Open to options: Lessons learned using an evidence-based treatment decision model for blood cancer patients in a community based setting

2010 ◽  
Author(s):  
M. F. Miller ◽  
J. Belkora ◽  
N. Blakeney ◽  
K. Coyne ◽  
B. Crawford ◽  
...  
Author(s):  
Rosario Costas-Muñiz ◽  
Olga Garduño-Ortega ◽  
Carlos Javier González ◽  
Xiomara Rocha-Cadman ◽  
William Breitbart ◽  
...  

Psychotherapeutic interventions focusing on addressing the needs and experiences of Latino cancer patients are scarce. This chapter discusses the formative process of the cultural and linguistic adaptation of meaning-centered psychotherapy (MCP) for Latinos with advanced cancer, as well as the considerations for and the process of adapting a psychotherapeutic intervention. A brief review of the efficacy of other psychotherapeutic interventions developed, adapted, and delivered to Latino cancer patients and also the concepts and applicability of individual meaning-centered psychotherapy are described. This chapter presents the initial phase of the adaptation of MCP, including conceptual frameworks, plan, process and methods used in adapting the original evidence-based treatment for Latino patients with advanced cancer. The mixed-method approach is described to provide future recommendations for clinicians, researchers, and program developers.


2020 ◽  
Vol 116 ◽  
pp. 105233
Author(s):  
Tamaki H. Urban ◽  
Thuy Trang T. Nguyen ◽  
Alexandra E. Morford ◽  
Tawny Spinelli ◽  
Zoran Martinovich ◽  
...  

2021 ◽  
Vol 81 (10) ◽  
pp. 1101-1111
Author(s):  
Andreas Schneeweiss ◽  
Peter A. Fasching ◽  
Tanja Fehm ◽  
Bernd Gerber ◽  
Christian Jackisch ◽  
...  

AbstractTherapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individual cases, other evidence-based treatment options may also be appropriate and justified. Regardless of approval status, the algorithms only take into account drugs that were available in Germany at the time the algorithm was last updated. Here we present the 2021 update of AGO treatment algorithms for early and metastatic breast cancer, which are intended to intensify structured treatment decision by providing reproducible and evidence-based treatment paths and may be helpful for a broad treatment landscape.


2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 92-92
Author(s):  
Daisy E. Escobar ◽  
Mohd Khushman ◽  
Jennifer Young Pierce ◽  
Cathy Tinnea ◽  
Austin Cadden ◽  
...  

92 Background: Lung cancer has the highest cause of cancer death, treatment of which is both complicated and expensive. Emerging actionable biomarkers and treatments provide both opportunity and treatment challenges. Adherence to evidence-based treatment and advanced care discussions add value to care. Oncology practices need to document the above to participate in value-based care reimbursement models. A Practice Transformation (PT) model was implemented to address quality and cost issues. Methods: After IRB approval, baseline data on lung cancer patients diagnosed during a 6-month period (Jul-Dec 2017) were collected through chart abstraction and treatment planning surveys. Rates of molecular testing ordered, results available at time of treatment decision-making, guideline concordant treatment decisions, and documentation of advanced care discussions were presented to the PT team. After education on recent clinical trial results and NCCN treatment guidelines, the PT team determined strategies for change. The PT team met after two 3-month periods of PT for education updates and progress reports. Data was compared on newly diagnosed patients during a 6-month period (Jul-Dec 2018), one year after the baseline period. Results: A total of forty-two patients were diagnosed in two 6-month periods, baseline and study period. Average age was 65 years, 57% male, 71% Caucasian, 95% ever smokers, 71% adenocarcinoma histology. Rate of ordering any molecular testing was (16/19) 84% in the baseline period vs (20/23) 86% in the study period. However, extended molecular testing increased from 16% (3/19) to 60% (12/20), p = .05 Fishers exact test. At treatment initiation, evidence-based treatment selections went from 47% to 52%. Documentation of advanced care discussions, 42% (8/19) to 56% (13/23), did not change significantly. Conclusions: A PT model that included education, and two cycles of implementation and feedback, resulted in increased molecular testing to inform evidence-based treatment selections. Increased awareness of the lack of documentation of advanced care discussions provides opportunity for continued improvement to effect quality care.


2008 ◽  
Vol 35 (3) ◽  
pp. 312-321 ◽  
Author(s):  
Van L. King ◽  
Christopher Burke ◽  
Kenneth B. Stoller ◽  
Karin J. Neufeld ◽  
Jessica Peirce ◽  
...  

2019 ◽  
Vol 2 (2) ◽  
Author(s):  
Jajang Ganjar Waluya ◽  
Nur Maziyya ◽  
Eva Nurlaela ◽  
Ita Vusfita ◽  
Ihda Al Adawiyah Mz ◽  
...  

Prevalence of  cancer is estimated will increase in the next two decades. Therefore, there is a challenge for health provider to encounter treatment and caring for the patients. Especially, the cancer patients face several problems not only physical but also psychological, emotional, spiritual and social cultural aspects.This study explored the evidence-based practice on community-based palliative cancer care. Literature study is done by making a summary of published articles related to the question. The searching method used several electronic databases such as Google Scholar, Proquest, and PubMed. Articles under the keywords of “Palliative Cancer Care”, “Community”, and “Nursing” reach as much as 1.804. The inclusion criteria for this literature review were articles that have been peer-reviewed, are in full-text, in either English or Indonesian, and publication year from 2008 to 2018. Meanwhile, the exclusion criteria include those that do not follow a standardized structure of an article (consisting of Abstract, Introduction, Method, Result, Discussion, Implication, and Reference), are in the form of a review, and whose content does not answer research questions.Results: The United States of America is on the highest place regarding palliative care service, following by community-based palliative cancer implementation in Europe. Asian countries had been applying palliative care service, integrated with national health care system. In the Middle East countries, palliative care program ranks the lowest, but in implementation, they have discreetly performed community-based palliative care. In Africa, it is not the main focus in the field of health. Palliative care for cancer patients that is potential for development in Indonesia is that of family-based.Conclusion: Community-based palliative care is a variant of palliative treatment long applied and being developed in many countries in the world. In continents such as America and Europe, the implementation of palliative care ranks the highest place. In Indonesia, it is done partially and only available in hospitals or non-governmental organization. In the level of community, family-based palliative care can be developed by involving trained family members.


2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 17-17
Author(s):  
Devika Govind Das ◽  
Avnish K Bhatia ◽  
Debra Wujcik ◽  
Susie Owenby ◽  
Wanda D. Hall ◽  
...  

17 Background: Most patients with non-small cell lung cancer (NSCLC) have advanced disease at diagnosis and are older with median age 72 years. Evidence-based treatment (EBT) selection requires availability of molecular testing (MT) results at time of treatment decision and geriatric assessment (GA) helps determine a patient’s ability to tolerate therapy. This study describes practice patterns and evidence based treatment selections of providers managing older patients with NSCLC. Methods: After provider education and using care planning software (CPS), 50 patients with advanced NSCLC from two academic centers completed surveys regarding treatment goals and decision-making preferences, and patients ≥ 65 completed a modified GA that included activities of daily living and comorbidity assessment. Once treatment was selected, a personalized care plan was generated. Comparison treatment data from 17 community patients was obtained. Results: Participants were mean age 65, 52% female, and 78% white. Of 28 stage IV patients, 79% had MT and results available at time of treatment decision, and 100% met EBT guidelines. The community cohort had 47% testing, 29% results available, and 65% met guidelines. GA results in 24 patients were 46% frail, 29% intermediate fit, and 25% fit. Two patients (8%) were frail and had a plan change due to GA results. Conclusions: Obtaining timely MT results remains challenging. Continued strategies to ensure MT and timely results should be explored, including quality assurance monitoring given the increasing importance of MT in treatment selection. GA was less impactful in this setting, likely due to later stage patients, presumed frailty, and treatment goal being palliation. We believe GA would have greater impact in early stage NSCLC where aggressive treatments are offered with curative intent.


Sign in / Sign up

Export Citation Format

Share Document